193 related articles for article (PubMed ID: 22155078)
21. Evidence in support of lysine 77 and histidine 96 as acid-base catalytic residues in saccharopine dehydrogenase from Saccharomyces cerevisiae.
Kumar VP; Thomas LM; Bobyk KD; Andi B; Cook PF; West AH
Biochemistry; 2012 Jan; 51(4):857-66. PubMed ID: 22243403
[TBL] [Abstract][Full Text] [Related]
22. N-terminal domain of tyrosyl-DNA phosphodiesterase I regulates topoisomerase I-induced toxicity in cells.
Brettrager EJ; Cuya SM; Tibbs ZE; Zhang J; Falany CN; Aller SG; van Waardenburg RCAM
Sci Rep; 2023 Jan; 13(1):1377. PubMed ID: 36697463
[TBL] [Abstract][Full Text] [Related]
23. Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide.
Davies DR; Interthal H; Champoux JJ; Hol WG
Chem Biol; 2003 Feb; 10(2):139-47. PubMed ID: 12618186
[TBL] [Abstract][Full Text] [Related]
24. Probing the evolutionary conserved residues Y204, F259, S400 and W590 that shape the catalytic groove of human TDP1 for 3'- and 5'-phosphodiester-DNA bond cleavage.
Kiselev E; Dexheimer TS; Marchand C; Huang SN; Pommier Y
DNA Repair (Amst); 2018; 66-67():64-71. PubMed ID: 29747024
[TBL] [Abstract][Full Text] [Related]
25. Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1).
Raymond AC; Staker BL; Burgin AB
J Biol Chem; 2005 Jun; 280(23):22029-35. PubMed ID: 15811850
[TBL] [Abstract][Full Text] [Related]
26. Structural basis for DNA 3'-end processing by human tyrosyl-DNA phosphodiesterase 1.
Flett FJ; Ruksenaite E; Armstrong LA; Bharati S; Carloni R; Morris ER; Mackay CL; Interthal H; Richardson JM
Nat Commun; 2018 Jan; 9(1):24. PubMed ID: 29295983
[TBL] [Abstract][Full Text] [Related]
27. Mutating His29, His125, His133 or His158 abolishes glycosylphosphatidylinositol-specific phospholipase D catalytic activity.
Raikwar NS; Bowen RF; Deeg MA
Biochem J; 2005 Oct; 391(Pt 2):285-9. PubMed ID: 15943582
[TBL] [Abstract][Full Text] [Related]
28. Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1.
Liu C; Pouliot JJ; Nash HA
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14970-5. PubMed ID: 12397185
[TBL] [Abstract][Full Text] [Related]
29. Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?
Hirano R; Interthal H; Huang C; Nakamura T; Deguchi K; Choi K; Bhattacharjee MB; Arimura K; Umehara F; Izumo S; Northrop JL; Salih MA; Inoue K; Armstrong DL; Champoux JJ; Takashima H; Boerkoel CF
EMBO J; 2007 Nov; 26(22):4732-43. PubMed ID: 17948061
[TBL] [Abstract][Full Text] [Related]
30. Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures.
Davies DR; Interthal H; Champoux JJ; Hol WG
J Mol Biol; 2002 Dec; 324(5):917-32. PubMed ID: 12470949
[TBL] [Abstract][Full Text] [Related]
31. Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts.
Brettrager EJ; van Waardenburg RCAM
Cancer Drug Resist; 2019; 2(4):1153-1163. PubMed ID: 31875206
[TBL] [Abstract][Full Text] [Related]
32. Tyrosyl-DNA phosphodiesterase and the repair of 3'-phosphoglycolate-terminated DNA double-strand breaks.
Zhou T; Akopiants K; Mohapatra S; Lin PS; Valerie K; Ramsden DA; Lees-Miller SP; Povirk LF
DNA Repair (Amst); 2009 Aug; 8(8):901-11. PubMed ID: 19505854
[TBL] [Abstract][Full Text] [Related]
33. Site-directed mutagenesis, kinetic and inhibition studies of aspartate ammonia lyase from Bacillus sp. YM55-1.
Puthan Veetil V; Raj H; Quax WJ; Janssen DB; Poelarends GJ
FEBS J; 2009 Jun; 276(11):2994-3007. PubMed ID: 19490103
[TBL] [Abstract][Full Text] [Related]
34. Pre-steady state kinetics of DNA binding and abasic site hydrolysis by tyrosyl-DNA phosphodiesterase 1.
Kuznetsov NA; Lebedeva NA; Kuznetsova AA; Rechkunova NI; Dyrkheeva NS; Kupryushkin MS; Stetsenko DA; Pyshnyi DV; Fedorova OS; Lavrik OI
J Biomol Struct Dyn; 2017 Aug; 35(11):2314-2327. PubMed ID: 27687298
[TBL] [Abstract][Full Text] [Related]
35. Spinocerebellar ataxia with axonal neuropathy.
Walton C; Interthal H; Hirano R; Salih MA; Takashima H; Boerkoel CF
Adv Exp Med Biol; 2010; 685():75-83. PubMed ID: 20687496
[TBL] [Abstract][Full Text] [Related]
36. Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy.
Dexheimer TS; Antony S; Marchand C; Pommier Y
Anticancer Agents Med Chem; 2008 May; 8(4):381-9. PubMed ID: 18473723
[TBL] [Abstract][Full Text] [Related]
37. Crystal structure of the catalytic fragment of human brain 2',3'-cyclic-nucleotide 3'-phosphodiesterase.
Sakamoto Y; Tanaka N; Ichimiya T; Kurihara T; Nakamura KT
J Mol Biol; 2005 Feb; 346(3):789-800. PubMed ID: 15713463
[TBL] [Abstract][Full Text] [Related]
38. SCAN1-TDP1 trapping on mitochondrial DNA promotes mitochondrial dysfunction and mitophagy.
Ghosh A; Bhattacharjee S; Chowdhuri SP; Mallick A; Rehman I; Basu S; Das BB
Sci Adv; 2019 Nov; 5(11):eaax9778. PubMed ID: 31723605
[TBL] [Abstract][Full Text] [Related]
39. Tyrosyl-DNA Phosphodiesterase I N-Terminal Domain Modifications and Interactions Regulate Cellular Function.
Brettrager EJ; Segura IA; van Waardenburg RCAM
Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31698852
[TBL] [Abstract][Full Text] [Related]
40. A new member of the alkaline phosphatase superfamily with a formylglycine nucleophile: structural and kinetic characterisation of a phosphonate monoester hydrolase/phosphodiesterase from Rhizobium leguminosarum.
Jonas S; van Loo B; Hyvönen M; Hollfelder F
J Mol Biol; 2008 Dec; 384(1):120-36. PubMed ID: 18793651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
